EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice

Bhawana Pandey iD, Zhengying Wang, Angela Jimenez, Eshant Bhatia, Ritika Jain, Alexander Beach, Drishti Maniar, Justin Hosten, Laura O'Farrell, Casey Vantucci, David Hur, Richard Noel und 4 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202402792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Bhawana Pandey und 15 weiteren Autor:innen. Beteiligte Einrichtung: Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Immunity, Mucosal, SARS-CoV-2, Administration, Intranasal, COVID-19 Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Robert A. Milton Chaired Professorship to Krishnendu Roy, National Institutes of Health- National Institute of Allergy and Infectious Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Existing parenteral SARS‐CoV‐2 vaccines produce only limited mucosal responses, essential for reducing transmission and achieving sterilizing immunity. Appropriately designed mucosal boosters can overcome the shortcomings of parenteral vaccines and enhance pre‐existing systemic immunity. Here, a new protein subunit nanovaccine is developed by utilizing dual‐adjuvanted (RIG‐I: PUUC RNA and TLR‐9: CpG DNA) polysaccharide‐amino acid‐lipid nanoparticles (PAL‐NPs) along with SARS‐CoV‐2 S1 trimer protein, that can be delivered both intramuscularly (IM) and intranasally (IN) to generate balanced mucosal‐systemic SARS‐CoV‐2 immunity. Mice receiving IM‐Prime PUUC+CpG PAL subunit nanovaccine, followed by an IN‐Boost, developed high levels of IgA, IgG, and cellular immunity in the lungs and showed robust systemic humoral immunity. Interestingly, as a purely intranasal subunit vaccine (IN‐Prime/IN‐Boost), PUUC+CpG PAL‐NPs induced stronger lung‐specific T cell immunity than IM‐Prime/IN‐Boost, and a comparable IgA and neutralizing antibodies, although with a lower systemic antibody response, indicating that a fully mucosal delivery route for SARS‐CoV‐2 vaccination may also be feasible. The data suggest that PUUC+CpG PAL subunit nanovaccine is a promising candidate for generating SARS‐CoV‐2 specific mucosal immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, MucosalSARS-CoV-2Administration, IntranasalCOVID-19 VaccinesCOVID-19NanoparticlesVaccines, SubunitAnimalsMiceAntibodies, ViralFemaleAdjuvants, VaccineSpike Glycoprotein, CoronavirusAdjuvants, ImmunologicAntibodies, NeutralizingMice, Inbred BALB CNanovaccines

Stichwörter der Autor:innen

SARS‐CoV‐2 subunit nanovaccineantiviral immunitycombination adjuvantsmucosal immunityparenteral and intranasal vaccinationpolymer nanoparticles

Substanzen

COVID-19 VaccinesVaccines, SubunitAntibodies, ViralAdjuvants, VaccineSpike Glycoprotein, CoronavirusAdjuvants, ImmunologicAntibodies, NeutralizingNanovaccines

Autor:innen und Institutionen

  • Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
  • Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
  • Physiological Research Laboratory, Georgia Institute of Technology, Atlanta, GA, USA.
  • The Parker H. Petit Institute for Bioengineering and Biosciences, School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
  • Wallace H. Coulter Department of Biomedical Engineering, The Parker H. Petit Institute for Bioengineering and Biosciences, Marcus Center for Therapeutic Cell Characterization and Manufacturing, Georgia Institute of Tech…
  • Department of Biomedical Engineering, Department of Chemical and Biomolecular Engineering, School of Engineering, Department of Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University, Nashvill…

ORCID-Profile: Bhawana Pandey, Krishnendu Roy

Förderung

  • NIAID NIH HHS
  • Robert A. Milton Chaired Professorship to Krishnendu Roy
  • National Institutes of Health- National Institute of Allergy and Infectious Disease
  • Georgia Tech Foundation

Zitieren

APA

Pandey, B., Wang, Z., Jimenez, A., Bhatia, E., Jain, R., Beach, A., Maniar, D., Hosten, J., O'Farrell, L., Vantucci, C., Hur, D., Noel, R., Ringquist, R., Smith, C., Ochoa, M. A., & Roy, K. (2024). A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice. Advanced Science. https://doi.org/10.1002/advs.202402792

Vancouver

Pandey B, Wang Z, Jimenez A, Bhatia E, Jain R, Beach A, et al. A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice. Advanced Science. 2024. doi:10.1002/advs.202402792

BibTeX
@article{Pandey2024,
  author = {Pandey, Bhawana and Wang, Zhengying and Jimenez, Angela and Bhatia, Eshant and Jain, Ritika and Beach, Alexander and Maniar, Drishti and Hosten, Justin and O'Farrell, Laura and Vantucci, Casey and Hur, David and Noel, Richard and Ringquist, Rachel and Smith, Clinton and Ochoa, Miguel A and Roy, Krishnendu},
  title = {A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202402792}
}
Kostenlos starten →